Japan’s Zeria To Start Phase III Trial For Functional Dyspepsia Therapy In Europe
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Zeria Pharmaceutical announced European Phase II double-blind trial results for Z-338 (acotimiade), a functional dyspepsia therapy developed by the company. The trial was conducted in 76 facilities and enrolled 473 patients from eight countries. According to the company, the result showed acotimiade effective compared to placebo and there was no safety issue. Zeria has decided to start consultation with European Medicines Agency on a Phase III trial, and the company also is considering partnering with other companies to speed up the development process. Japanese major drug maker Astellas has licensed the drug's exclusive rights in the U.S., and the two companies are jointly conducting a Phase II trial. In Japan, Zeria and Astellas collaborate on an ongoing Phase III trial. In Japan, one in every four adults is found to have FD symptoms. (Click here for more - Japanese language
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.